These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 3698168

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG).
    Erdélyi-Tóth V, Kerpel-Fronius S, Kanyár B, Eckhardt S.
    Cancer Chemother Pharmacol; 1986; 16(3):257-63. PubMed ID: 3698167
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Eagan RT, Moertel CG, Hahn RG, Schutt AJ.
    J Natl Cancer Inst; 1976 Jan; 56(1):179-81. PubMed ID: 943554
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol.
    Kerpel-Fronius S, Erdélyi-Tóth V, Somfai-Relle S, Csetényi J, Kovács P, Ujj G, Kanyár B.
    Cancer Chemother Pharmacol; 1988 Jan; 22(2):109-13. PubMed ID: 3409440
    [Abstract] [Full Text] [Related]

  • 6. [Apoptosis induced by diacetyldianhydrogalactitol and its mechanism in HL-60 leukemia cells].
    Yang JN, Liu JY, Xu H, Liu XL, Qin Y.
    Yao Xue Xue Bao; 2002 Sep; 37(9):691-5. PubMed ID: 12567892
    [Abstract] [Full Text] [Related]

  • 7. [Effects of 1,2:5,6-dianhydrogalactitol on the bone marrow stem cells in normal and melanoma-bearing mice (author's transl)].
    Fan YJ, Li M, Zhou J.
    Zhongguo Yao Li Xue Bao; 1980 Dec; 1(2):112-5. PubMed ID: 6461181
    [No Abstract] [Full Text] [Related]

  • 8. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.
    J Natl Cancer Inst; 1993 Aug 18; 85(16):1319-26. PubMed ID: 8340944
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 18; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

  • 10. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.
    Adamson PC, Balis FM, Miser J, Arndt C, Wells RJ, Gillespie A, Aronson L, Penta JS, Clendeninn NJ, Poplack DG.
    Cancer Res; 1992 Feb 01; 52(3):521-4. PubMed ID: 1732038
    [Abstract] [Full Text] [Related]

  • 11. Anticancer activity and mechanisms of diacetyldianhydrogalactitol on hepatoma QGY-7703 cells.
    Zhang XY, Lian Yan X, Guo W, Xu B, Li M, Zhou Y, Rong Cui J.
    Anticancer Drugs; 2009 Nov 01; 20(10):926-31. PubMed ID: 19741503
    [Abstract] [Full Text] [Related]

  • 12. Biochemical changes of intestinal epithelial cells induced by cytostatic agents in rats.
    Kralovánszky J, Prajda N.
    Arch Toxicol Suppl; 1985 Nov 01; 8():94-103. PubMed ID: 3868386
    [Abstract] [Full Text] [Related]

  • 13. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
    van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM.
    Cancer Res; 1986 Sep 01; 46(9):4831-6. PubMed ID: 2425959
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
    Thigpen JT, Al-Sarraf M, Hewlett JS.
    Cancer Treat Rep; 1979 Apr 01; 63(4):525-8. PubMed ID: 445506
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
    Grochow LB, Noe DA, Ettinger DS, Donehower RC.
    Cancer Chemother Pharmacol; 1989 Apr 01; 24(5):314-20. PubMed ID: 2758561
    [Abstract] [Full Text] [Related]

  • 17. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.
    J Clin Oncol; 1996 Jul 01; 14(7):2020-30. PubMed ID: 8683232
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
    Hendricks CB, Grochow LB, Rowinsky EK, Forastiere AA, McGuire WP, Ettinger DS, Sartorius S, Lubejko B, Donehower RC.
    Cancer Res; 1991 Nov 01; 51(21):5781-5. PubMed ID: 1933848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.